- Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain
- Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain
- Cannabis, pain, and sleep: Sativex Clinical Trials
- Sativex successfully treats neuropathic pain characterised by allodynia: clinical trial
- Cannabinoids for neuropathic pain
- Neuropathic orofacial pain: Cannabinoids as a therapeutic avenue
- Oromucosal delta9-THC/CBD for neuropathic pain associated with multiple sclerosis
- The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain
- Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation
- Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy
- Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain
- Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action
- Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors
- Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes
- Cannabinoids in the management of difficult to treat pain
- Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain
- Marijuana extract helps prevent chemo pain
- Pot users less likely to take painkillers